Sex-dependent locus coeruleus vulnerability in Alzheimer’s disease: gut dysbiosis as a driver and probiotic intervention as rescue

Abstract

Alzheimer’s disease (AD) displays striking sex differences in incidence, progression, and resilience, yet the mechanisms that drive female-biased vulnerability remain incompletely understood. Emerging evidence indicates that gut dysbiosis, increasingly prevalent with ageing, acts as a systemic amplifier of neuroinflammation, vascular instability, and metabolic dysfunction. Here, we synthesize converging findings linking gut microbial alterations to noradrenergic pathology in the locus coeruleus (LC), one of the earliest brain regions affected in AD. We outline how dysbiosis-associated inflammatory signaling, including endotoxin exposure and impaired vagal-neuroimmune regulation, targets LC circuits. In parallel, disruptions in microbial metabolite pathways involving short-chain fatty acids, bile acids, and tryptophan metabolism further promote oxidative stress, tau phosphorylation, and neurodegeneration. We further argue that sex-dependent differences in immune reactivity, autonomic regulation, and hormonal transitions, particularly peri- and post-menopausal estrogen decline, render female LC neurons uniquely vulnerable to microbial and inflammatory perturbation. We propose a mechanistic framework in which gut dysbiosis destabilizes LC integrity through parallel immune-vascular, metabolite, endocrine, and vagal neural pathways, thereby accelerating cognitive decline and AD progression. Understanding how microbial signaling intersects with sex biology and neuromodulatory circuitry may reveal therapeutic windows for early intervention, including microbiome restoration, neuromodulatory tuning, and sex-specific metabolic targeting.

Introduction

Alzheimer’s disease (AD) pathogenesis unfolds along trajectories shaped by both intrinsic neural circuit vulnerability and systemic modifiers such as sex hormones and the gut microbiome. Among neuromodulatory hubs, the locus coeruleus (LC), the brain’s principal source of norepinephrine (NE), is uniquely positioned as a convergence site where metabolic, inflammatory, and hormonal stressors interact to influence cognitive resilience and degeneration [1]. Compelling evidence indicates that LC neurons accumulate pretangle tau decades before cortical pathology emerges, linking early noradrenergic dysfunction to prodromal cognitive decline [2–4]. Notably, LC architecture, stress responsivity, and immune coupling exhibit pronounced sex differences [5, 6], suggesting that biological sex and hormonal milieu critically shape LC susceptibility cross aging and disease.

Here, we propose a Gut–LC–Sex Convergence Hypothesis, in which sex-biased LC vulnerability in AD arises from the coordinated interaction of circulatory, immune, hormonal, vagal, and metabolic pathways, with gut dysbiosis acting as a systems-level amplifier. This integrative framework accounts for a female-biased breach of LC resilience, particularly during peri- and post-menopausal transitions, and distinguishes the present review from prior accounts that consider only isolated components of this network. The following sections synthesize preclinical and clinical evidence supporting this model and highlight emerging therapeutic opportunities targeting this nexus in AD.

Sex-dependent LC vulnerability in AD: preclinical and clinical findings

Across species, the LC-NE system calibrates arousal, attention, synaptic plasticity, microglial tone, and vascular dynamics, precisely the domains that drift early in AD [7–11]. Neuropathology places pretangle tau in LC neurons decades before clinical symptoms [2, 12–14]. Converging human imaging [15–18] and postmortem work [19–21] links LC integrity to cognition and AD progression, positioning LC measures as candidate prodromal biomarkers. Preclinical models reinforce causality: LC insults worsen amyloid deposition, neuroinflammation, network instability, and behavioral decline [22–25]; conversely, preserving LC‑NE signaling can rescue cognition and synaptic plasticity [26, 27].

Rodent work consistently identifies sex differences in LC macro‑ and micro‑architecture and stress coupling. Females typically show larger LC volume, greater neuron number, and more elaborate dendrites [6, 28–31]. Estrogen can up‑regulate tyrosine hydroxylase and boost NE synthesis [32, 33], while corticotropin‑releasing factor (CRF) signaling is biased toward prolonged Gs‑coupling in females, reducing receptor internalization and heightening stress sensitivity [34–37]. These features may enhance performance in optimal contexts yet increase metabolic and oxidative load during chronic adversity, amplifying vulnerability with aging and disease. Transcriptomic [38] and proteomic data [39] point to female‑specific stress pathways in LC neurons.

In LC-focused tauopathy models, including fibril seeding in PS19 and P301 lines [40, 41], LC-targeted pseudophosphorylated tau (htauE14) [42], and TgF344-AD models [27], tau pathology arises early, producing axonal degeneration, circuit dysfunction, and learning impairments prior to widespread cortical tangle formation. While earlier studies often pooled sexes, recent LC-specific htauE14 work reveals marked sex-divergent molecular and inflammatory responses, aligning with a female-biased vulnerability to tau stress [43, 44]. In this pretangle model, males show robust upregulation of NE biosynthetic genes, indicative of a compensatory response aimed at maintaining noradrenergic signaling in the face of tau-induced axonal degeneration. In contrast, females exhibit broader shifts in metabolic and developmental programs that may reflect alternative adaptive strategies shaping differential resilience [44].

Neuromelanin‑sensitive MRI have transformed LC research. Across aging and AD, lower LC integrity relates to greater tau burden and worse cognition [16–18]. However, sex effects remain under‑sampled or inconsistently analyzed: several cohorts report no macrostructural sex differences [45, 46], whereas others show lower [15] or higher [47, 48] neuromelanin-sensitive LC signal intensity in females compared to males. Additionally, studies have reported elevated functional connectivity [49, 50] and increased metabolism [51] in older females during the preclinical stages of AD, suggesting compensatory mechanisms that may confer resilience and slow disease progression. Methodological variation, limited stratification by menopausal status or hormone therapy, and disease stage mixing (preclinical, MCI, AD stages) likely blur sex‑dependent signals. Taken together, these findings position the LC as an early, behaviorally relevant node in human AD, underscoring the need for sex-aware longitudinal imaging integrated with fluid and genetic risk markers.

Gut dysbiosis in ageing and Alzheimer’s disease: sex-dependent patterns

Ageing and AD are consistently associated with a shift in gut microbial composition characterized by reduced diversity, loss of short-chain fatty acid (SCFA) producers (e.g., Bifidobacterium, Faecalibacterium), and expansion of pro-inflammatory taxa such as Escherichia and broader Proteobacteria [52–54]. These changes weaken intestinal barrier integrity, increasing translocation of lipopolysaccharides (LPS) and other microbial products into the circulation, where they amplify systemic cytokine load (IL-6, TNF-α, IL-1β) and activate downstream immune signaling [52, 53, 55]. In the brain, this inflammatory pressure promotes blood-brain barrier (BBB) leakage, microglial priming, astrocytic reactivity, β-amyloid aggregation, tau phosphorylation, and ultimately neurodegeneration [4, 53, 55].

In parallel with the humoral immune route, gut dysbiosis also influences the brain through neural, metabolic, and endocrine channels [56]. One major communication pathway is vagal afferent signaling, which rapidly conveys microbial and visceral information directly to brainstem nuclei. Dysbiosis additionally modifies the production of microbial metabolites, including SCFAs, tryptophan-kynurenine derivatives, and bile acids, all of which can regulate neuronal excitability, microglial activation, and metabolic homeostasis. A further layer of communication arises from enteroendocrine hormones such as glucagon-like peptide-1 (GLP-1), ghrelin, and cortisol, which act on hypothalamic and limbic targets or modulate synaptic plasticity and neuroimmune tone [53, 56, 57].

Preclinical and clinical studies converge on the same pattern: dysbiosis tracks with cognitive decline, neuroinflammation, and proteinopathy, while interventions that restore microbial balance such as probiotics, prebiotics, antibiotics, or fecal transfer, can improve cognition and reduce neuroinflammatory markers [53–55]. In animal models, disrupted microbial balance increases Aβ deposition, tau phosphorylation, neuroinflammation, and cognitive impairment [58, 59], potentially driven by cGAS-STING and NLRP3 inflammasome activation [59–63]. Fecal microbiota transplantation (FMT) from AD patients into mice inducing Aβ/tau aggregation and synaptic injury, accompanied by elevated IL-1β, IL-18, and TNF-α [63, 64]. Human evidence aligns with this pattern. Clinical studies report that individuals with dysbiosis show lower microbial diversity, metabolic imbalance, and cognitive deterioration, and that FMT from healthy donors improves cognitive scores and alters metabolic signatures in AD and mild cognitive impaired (MCI) patients [65–67].

Therapeutically, microbiome-directed interventions reliably reverse pathology: probiotics reduce Aβ production and microglial activation in amyloid precursor protein (APP) knock-in mice [68] and ameliorate cognitive impairment via AKT/GSK-3β signalling modulation in aged AD-prone mice [69], while clinical probiotic supplementation improves cognition, reduces inflammatory markers, and promotes oxidative balance in mild-to-moderate AD [70, 71], with no effects in advanced stages [72]. Additionally, preclinical antibiotic depletion of gut flora reduces amyloid burden and slows disease progression [73], further demonstrating that manipulating the microbiome can modify AD trajectory rather than simply correlate with it. Together, these studies reinforce the interpretation that dysbiosis is mechanistically linked to both cognitive and pathological burden in AD, and that restoring microbial ecology can rescue cognition, reduce neuroinflammatory tone, and attenuate proteinopathy, especially at early or preclinical stages.

Despite broad parallels in how dysbiosis interfaces with AD, biological sex introduces divergence at nearly every level of this axis. Male and female microbiota differ across life in taxonomic composition, metabolite profiles, bile-acid metabolism, vagal sensitivity, and inflammatory tone [74–79]. Sex hormones such as estrogen and progesterone influence immune function and microglial reactivity. These hormonal signals fluctuate across the reproductive cycle, altering immune tone and microbial balance. With peri- and post-menopausal estrogen decline, these shifts become more pronounced, reconfiguring gut microbial communities and increasing vulnerability to AD [80]. Menopause-associated estrogen loss, in particular, reduces SCFA-producing taxa, elevates inflammatory signaling, and disrupts vascular-metabolic balance [81, 82], collectively creating a more permissive landscape for neurodegeneration. Additional modifiers, including diet, aging, physical activity, sleep, and geography, interact with sex to reshape the microbiota and influence disease trajectory [80]. Consistent with this, clinical cohorts show female-biased microbiome signatures tied to immune and metabolic status that parallel AD risk [52, 80, 83], while experimental models reveal heightened inflammatory reactivity and increased susceptibility to neuromodulatory stress in females, especially under conditions of noradrenergic decline [38, 85–87].

Together, these findings position dysbiosis as a sex-modulated upstream driver of neurodegenerative vulnerability (Fig. 1). As Sect. “Why the locus coeruleus is particularly susceptible to dysbiosis: Sex-ependent mechanistic pathways and evidence for intervention” details, this imbalance does not act in isolation, it converges on the LC, a neuromodulatory hub exceptionally sensitive to inflammatory, metabolic, and hormonal perturbation. We propose that age- and menopause-linked microbial shifts form a systemic pressure point that disproportionately destabilizes noradrenergic homeostasis in females, accelerating LC degeneration and cognitive decline in AD.

Fig. 1.

Sex-dependent pathways linking gut dysbiosis to neurodegenerative processes in the brain. ⚥ indicates gut-brain pathways shared by females and males (left), whereas ♀ and ♂ denote sex-specific aspects of gut microbiome dynamics Gut dysbiosis shifts microbial composition and disrupts normal metabolite production. Beneficial metabolites such as SCFAs, bile acids, and tryptophan-kynurenine derivatives decline, while pro-inflammatory taxa increase. Together, these alterations influence the brain through several interconnected pathways. Microbial products (e.g., LPS, IL-6, TNF-α, IL-1β) cross gut and vascular barriers, enter circulation, and promote leukocyte and neutrophil activation that contributes to blood-brain barrier permeability and inflammatory signaling. Dysbiosis also disrupts enteroendocrine communication (GLP-1, ghrelin, cortisol) and modulates vagal afferent pathways, leading to aberrant neural signaling toward brainstem and forebrain regions. These converging inputs promote microglial activation, reactive astrocytosis, tau hyperphosphorylation, amyloid accumulation, and neuronal degeneration. Sex differences influence every stage of this gut-brain axis, including microbial taxonomic profiles, metabolite balance, bile-acid dynamics, vagal sensitivity, and inflammatory tone, resulting in distinct trajectories of neuroimmune stress and neurodegenerative vulnerability in females and males. Generated with BioRender.com

Why the locus coeruleus is particularly susceptible to dysbiosis: sex-dependent mechanistic pathways and evidence for intervention

The gut-brain axis forms a bidirectional communication network linking intestinal microbes with central neuromodulatory systems through neural, immune, endocrine, and metabolic routes [56, 57]. Within this framework, the LC stands out not simply as a relay, but as a high-gain integrator of visceral and inflammatory signals, owing to its dense capillary supply, proximity to permeable brainstem regions, and reciprocal connections with autonomic nuclei [1, 87]. High oxidative demand and an extensive projection architecture further heighten its sensitivity to peripheral perturbations, particularly those arising from microbial imbalance.

Emerging evidence suggests that dysbiosis may not only accompany aging and AD progression but operate upstream, priming LC physiology for degeneration. Microbiota shifts during dysbiosis reduce SCFA-mediated trophic support, elevate cytokine-driven inflammatory tone, and disrupt vagal and hypothalamic-pituitary axis (HPA) dynamics, creating multiple biological access points through which gut signals destabilize LC homeostasis. These pathways can activate microglia, intensify oxidative stress, and disturb noradrenergic output, effectively lowering the threshold for tau phosphorylation and synaptic loss.

Taken together, gut dysbiosis emerges as a vulnerability amplifier for the LC, with susceptibility shaped by sex-dependent differences in immune responsivity, steroid hormone signaling, and neuromodulatory feedback. The following subsections delineate five mechanistic routes through which microbial imbalance can influence LC integrity including circulatory, immune, hormonal, vagal, and metabolic/neurochemical, highlighting points of sex-specific divergence (Fig. 2).

Fig. 2.

Sex-dependent gut-brain pathways converging on LC vulnerability in Alzheimer’s disease. ⚥ indicates features of LC vulnerability shared by females and males, whereas ♀ denotes female-specific gut microbiome features and heightened CRF responsiveness in the LC. Estrogen molecular structure denotes estrogen-modulated processes The gut microbiome communicates with the brain through circulatory, immune, hormonal, vagal, and metabolic pathways that collectively converge on the LC, each subject to sex-dependent modulation. Estrogen promotes microbial diversity, epithelial barrier integrity, and short-chain fatty acid (SCFA) production, whereas its decline with menopause reduces SCFAs, increases gut permeability, and heightens inflammatory tone. Females show stronger immune activation, greater ROS/NO vascular signaling, and higher vagal sensitivity with enhanced GABAergic modulation; estrogen also regulates β-glucuronidase activity, norepinephrine (NE) synthesis, and bile-acid metabolism. LC neurons exhibit female-biased CRF sensitivity and estrogen-dependent NE regulation, increasing vulnerability as hormonal support diminishes. Because LC neurons have high oxidative demand, long unmyelinated axons, and close vascular apposition, they readily encounter cytokines, LPS, and toxic catecholamine metabolites. Together, these sex- and hormone-dependent factors link gut dysbiosis and endocrine decline to LC oxidative stress and neurodegeneration, positioning the LC as a central convergence node and a promising target for microbiome-based interventions. Abbreviations: LC, locus coeruleus; NE, norepinephrine; SCFA, short-chain fatty acid; CRF, corticotropin-releasing factor; HPA, hypothalamic-pituitary-adrenal axis; ROS, reactive oxygen species; NO, nitric oxide; LPS, lipopolysaccharide; DOPEGAL, 3,4-dihydroxyphenylglycolaldehyde. Generated with BioRender.com

Circulatory and vascular pathway

Situated adjacent to the fourth ventricle and endowed with an exceptionally dense capillary network, the LC exhibits circumventricular organ-like features that increase its exposure to circulating mediators [88]. Indeed, perivascular noradrenergic terminals originating from the LC closely abut intracortical blood vessels and astrocytic processes, underscoring the LC’s intimate vascular-glial interface and vulnerability to systemic influences [89]. Gut dysbiosis elevates circulating LPS and inflammatory cytokines, inducing endotoxemia and compromising the BBB [90, 91]. LC neurons, characterized by thin myelination and perivascular positioning [89, 92, 93], are among the earliest neuronal populations to encounter these infiltrating molecules. Under physiological conditions, NE released from LC terminals maintains vascular tone and supports BBB stability [89, 94, 95]. Thus, LC degeneration diminishes NE-dependent vascular regulation and exacerbates barrier leakage and oxidative injury [22], creating a self-reinforcing cycle of vulnerability.

Estrogen confers vascular protection by enhancing nitric-oxide (NO) signaling and antioxidant defense [96–98], mitigating these insults in premenopausal females. With menopause, estrogen decline removes this protective buffer, therefore rendering the female LC more susceptible to vascular and oxidative stress. Consistent with this, both clinical and experimental models of estrogen deficiency demonstrate endothelial dysfunction, increased reactive oxygen species (ROS), and diminished NO bioavailability [99–101]. These impairments are reversed by estrogen replacement [102], indicating that hormonal loss alone is sufficient to precipitate vascular and oxidative injury. Notably, women also show a disproportionately higher mortality risk from cardiovascular disease [103], reflecting a broader trend in which sex-dependent biological mechanisms influence vulnerability and clinical outcomes across systems.

Immune and inflammatory pathway

Gut dysbiosis compromises intestinal barrier integrity, permitting microbial antigens and metabolites to enter circulation and activate systemic immune cascades [56, 57]. Elevated cytokines such as IL-6 and TNF-α can penetrate permeable brain regions, stimulating microglial and astrocytic activation within the LC and initiating neuroinflammatory responses [4, 43]. The LC’s intrinsically high oxidative metabolism, driven by pacemaker-like autonomic firing [104], together with its neuromelanin accumulation, intensifies vulnerability to such insults [105]. Neuromelanin supports cellular resilience in healthy LC neurons, yet when released from degenerating cells it becomes pro-inflammatory, driving mitochondrial injury and elevating reactive oxygen species [106, 107]. Females typically mount stronger innate and adaptive immune responses, a process tightly modulated by estrogen and progesterone [108, 109]. With hormonal decline of peri- and menopause, anti-inflammatory signaling weakens and glial cells become primed for exaggerated reactivity. This sex-biased immune amplification further renders the LC as a particularly vulnerable target for inflammatory damage during aging and neurodegenerative disease.

Hormonal and endocrine pathway

The gut microbiota-estrogen axis provides a metabolic-endocrine bridge between intestinal function and LC neuromodulatory regulation. Circulating estrogen levels are strongly shaped by microbial metabolism [110]. Following hepatic conjugation, estrogens are secreted into bile as biologically inactive glucuronide and sulfate conjugates [111, 112], then reactivated in the intestine where bacterial β-glucuronidases and hydroxysteroid dehydrogenases convert them back into biologically active hormones [113–115]. These recycled estrogens re-enter circulation and reach the brain, where LC-expressed ERα and ERβ [116] regulate noradrenergic tone - baseline and dynamic range of NE synthesis and release, by modulating tyrosine hydroxylase [32, 117] and catechol-O-methyltransferase [118]. Through this route, microbial metabolism of estrogens shapes LC bioenergetics, enhancing NE turnover, mitochondrial efficiency, and antioxidant capacity to support metabolic stability.

Dysbiosis that reduces estrogen-reactivating bacteria lowers circulating estradiol [119], weakening these neuroprotective mechanisms and blunting LC NE output. During menopause, the dual decline in microbial β-glucuronidase activity [120] and ovarian estrogen production acts synergistically to depress systemic estrogen levels, thereby compromising LC energy metabolism and resilience to oxidative stress.

Sex strongly shapes this endocrine coupling. In females, estrogen-driven feedback between the gut microbiota, circulation, and LC receptor signaling serves as a primary regulatory axis, whereas in males, androgenic pathways more prominently govern stress reactivity and metabolic homeostasis [121, 122]. Androgens such as testosterone and dihydrotestosterone engage receptors in hypothalamic, amygdalar, and brainstem autonomic nuclei to restrain CRF-dependent HPA activation and tonic sympathetic output [121, 123, 124], enhancing metabolic efficiency and reducing oxidative burden in LC neurons.

Under normal conditions, estrogenic signaling and microbiome-mediated estrogen recycling provide metabolic buffering within the LC, sustaining NE synthesis, mitochondrial efficiency, and antioxidant defenses even during periods of heightened stress [5, 125]. When either of these supports diminishes during peri- and menopause, dysbiosis, inflammation, or impaired enterohepatic cycling, metabolic stability may erode, potentially reducing the precision of LC firing and increasing the energetic cost of noradrenergic output. Reduced mitochondrial resilience would be expected to elevate ROS generation and lower recovery capacity, predisposing LC neurons to excitotoxic strain and degeneration [126]. This model offers a mechanistic basis for heightened LC stress sensitivity in peri-menopausal females, and for why gut dysbiosis may exacerbate noradrenergic vulnerability in AD.

Notably, metabolic dysregulation increases during peri- and post-menopause [127], and women with metabolic disorders show a higher likelihood of early menopausal onset [128, 129], highlighting a bidirectional feedback loop in which metabolic strain accelerates estrogen decline and reduced estrogen further destabilizes LC energetics. In this framework, microbial imbalance, hormonal depletion, and metabolic vulnerability do not act independently, but converge to produce a female-biased breach of LC resilience.

Vagal and neuroautonomic pathway

The vagus nerve serves as the primary conduit linking gut physiology to the LC. Vagal afferents project to the nucleus tractus solitarius (NTS), which provides excitatory input to the LC and allows visceral states to modulate noradrenergic output [126, 130–132]. Vagus nerve stimulation preferentially activates myelinated vagal fibers, generating temporally patterned NTS bursts that induce phasic LC firing, enhancing signal-to-noise processing and adaptive arousal [126, 131]. In contrast, inflammatory cytokines activate hypothalamic CRF circuits via vagal afferent signaling [133], increasing CRF release onto LC neurons, a mechanism well-known to shift LC activity toward sustained tonic firing, hyperarousal, and stress responsivity [5, 84, 134, 135].

Gut dysbiosis increases intestinal permeability and circulating IL-1β, TNF-α, and IL-6, thereby heightening vagal inflammatory signaling and HPA-CRF drive [133, 136, 137]. We propose that gut dysbiosis-associated inflammation preferentially engages HPA-CRF signaling, biasing LC neurons toward tonic, stress-like firing [138, 139]. This tonic mode competes with and can override the vagus nerve-NTS-LC pathway, which normally promotes phasic, stimulus-locked LC activity that supports attention, learning, and cognitive flexibility. Under conditions of sustained inflammatory or stress signaling, CRF-driven tonic firing dominates, reducing the influence of vagal phasic inputs and shifting LC output toward anxiety-related and maladaptive behavioral states (Fig. 3).

Fig. 3.

Sex-dependent vagal and HPA pathways linking gut dysbiosis to LC modulation. ♀ indicates female-specific vagal features (left) and female-biased LC responses to HPA-axis signaling (right) Gut-derived signals reach the LC through two major neural routes: the vagus nerve via the nucleus tractus solitarius (NTS; green arrows) and inflammatory-stress pathways via the hypothalamic-pituitary-adrenal (HPA) axis, which can also engage vagal pathways (red arrows). Under healthy conditions, microbial metabolites such as short-chain fatty acids (SCFAs), GABA, and serotonin (5-HT) enhance vagal afferent activity and support phasic LC firing. Dysbiosis reduces these metabolites while increasing pro-inflammatory cytokines (IL-1β, IL-6, TNF-α), which drive HPA activation and corticotrophin-releasing factor (CRF)-mediated tonic LC hyperactivity. Sex differences influence both pathways: females typically show higher vagal tone, more myelinated Ah-type vagal afferents, and greater vagal fascicle number, while LC neurons exhibit female-biased CRF sensitivity. Together, these factors create a sex-dependent bias in how gut-derived signals shape LC activity and stress responsivity. Generated with BioRender.com

Dysbiosis also alters vagal tone through microbial metabolites and neurotransmitters, notably reducing SCFAs such as acetate, propionate, and butyrate [140]. SCFAs modulate vagal excitability both directly and indirectly: they act through GPR41/43 signaling on enteroendocrine and enteric neurons, stimulating the release of gut peptides such as GLP-1 and PYY that fine-tune vagal afferent firing and promote sustained suppression of peripheral inflammatory signaling [142–144]. In addition, SCFAs, particularly butyrate, enhance GABAergic signaling via histone deacetylase inhibition and increased GABA synthesis [144], effects that may contribute to the inhibitory tone regulating vagal output [141, 145]. When SCFA levels decline, this inhibitory control is weakened, producing erratic or tonic vagal firing which activates hypothalamus CRF neurons, consequently, sustained excitatory drive to the LC. Such dysregulation promotes LC overactivation, oxidative stress, and reduced cognitive function.

Sex potentially shapes vagal-LC coupling at both the afferent and central levels. In humans, premenopausal women exhibit higher cardiac vagal tone and more favorable autonomic balance than age-matched men, an effect that is closely linked to circulating estradiol and diminishes after menopause [146]. In rodents, vagal sensory neurons express estrogen receptors and show marked female-biased specializations: a myelinated Ah-type afferent population is more prevalent in females, its excitability is reduced by ovariectomy and restored by 17β-estradiol [147, 148]. Recent human anatomical work further suggests subtle sex dimorphism in the vagus nerve itself. Women display a greater number of fascicles, particularly in the right cervical vagus, potentially increasing channel capacity for visceral signaling [149]. On the efferent side, parasympathetic output to the gut arises from the dorsal motor nucleus of the vagus and nucleus ambiguus, where androgen receptors are abundant [150], indicating that androgens can modulate vagal motor neurons and metabolic/autonomic outflow.

In summary, these peripheral and brainstem differences interface with a sexually dimorphic LC (Fig. 3). LC-NE neurons in females differ in number, morphology, excitability, and stress responsivity from males [6]. Whole-brain rabies “projectome” mapping shows that female LC receives a relatively higher proportion of inputs from midbrain and hindbrain including autonomic regions, whereas male LC is more heavily innervated by cerebrum and interbrain structures [151]. In the context of gut dysbiosis, increased IL-1β, TNF-α, and IL-6 engage vagal afferents and hypothalamic CRF circuits, which in turn bias LC firing toward a tonic, stress-like mode [34]. When estrogen declines, female-biased vagal afferent sensitivity, reduced autonomic protection, and stronger hindbrain input to LC together provide a mechanistic framework for why dysbiosis and inflammatory load may more readily translate into LC hyperarousal, anxiety, and cognitive impairment in females than in males.

Metabolic and neurochemical pathway

Microbial metabolites including SCFAs, bile acids, and tryptophan derivatives, act as neuromodulators influencing LC function. Under healthy conditions, SCFAs such as butyrate normally strengthen gut barrier integrity, suppress inflammation, and inhibit the expansion of harmful bacteria [152, 153]. When SCFAs are reduced, barrier function weakens and oxidative and immune stress increase [145], a pattern consistently observed in inflammatory bowel diseases [154].

The gut microbiome strongly shapes both tryptophan metabolism [155] and bile-acid metabolism [156], each of which contributes to neuromodulatory signaling in distinct ways [157, 158]. Disruptions in these metabolic pathways can alter LC activity through downstream mechanisms, including farnesoid X receptor (FXR)-mediated bile-acid signaling and serotonin-dependent pathways, that directly modulate autonomic tone [159, 160].

Under physiological conditions, bile acids act as signaling molecules that activate FXR and TGR5 receptors in peripheral and central autonomic circuits, helping maintain metabolic homeostasis and balanced autonomic output [161, 162]. Gut dysbiosis disrupts bile-acid metabolism, lowering secondary bile-acid production [163] and weakening TGR5 signaling [164]. Because TGR5 is selective for secondary bile acids [165], this impairment heightens inflammation [166] and contributes to broader metabolic dysfunction [167].

Similarly, gut microbial imbalances shift tryptophan metabolism away from the serotonin pathway toward the kynurenine pathway, reducing central serotonin availability [168] and generating toxic kynurenine metabolites that promote neuroinflammation [169]. Because serotonin normally provides inhibitory modulation of LC neurons through 5-HT₂A receptors [170], this shift disinhibits LC firing and promotes a tonic, stress-like state. Together, bile-acid and tryptophan dysregulation reinforce autonomic imbalance and noradrenergic overactivation, exacerbating LC vulnerability to metabolic and inflammatory stress.

Sex differences further shape these metabolic pathways. In humans, males generally maintain larger bile-acid pools [171], whereas in mice young females show the larger pools [172, 173]. Estrogen regulates bile-acid synthesis and FXR-dependent feedback control of cholesterol and lipid metabolism [174, 175], in part by suppressing CYP7A1 and thereby maintaining a smaller, tightly regulated bile-acid pool in females [176]. After menopause, declines in both estrogen and microbial SCFA production weaken this metabolic buffering, reducing antioxidant capacity and mitochondrial efficiency [177, 178]. The combined loss of hormonal and microbial regulation heightens redox imbalance and catecholaminergic stress, could contribute to the increased LC vulnerability observed in females.

The locus coeruleus: convergence node and probiotic rescue target

Together, these five pathways define the LC as a hub of convergence where circulatory, immune, hormonal, autonomic, and metabolic signals intersect (Fig. 2; Table 1). Under healthy conditions, NE output, estrogen signaling, and microbial metabolites maintain vascular, immune, and stress balance. Dysbiosis dismantles this homeostasis, provoking systemic inflammation, hormonal imbalance, and altered vagal signaling, that collectively overburden LC neurons. Female-specific traits including stronger immune reactivity, estrogen-linked vascular control, and higher vagal tone, magnify this coupling, producing a sex-biased vulnerability axis that aligns with women’s higher AD risk and earlier LC decline [3].

Table 1.

Gut-Brain communication pathways influencing LC vulnerability and sex modulation

Pathway	Gut-Brain Communication during Dysbiosis	Impact on Locus Coeruleus (LC)	Sex Differences/Modulation	Key Mediators
1. Circulatory/Vascular	Gut dysbiosis elevates circulating LPS and cytokines (IL-6, TNF-α, IL-1β), leading to systemic inflammation and BBB disruption.	LC, near the fourth ventricle with dense capillaries, is directly exposed to circulating toxins; NE loss further weakens vascular tone and BBB integrity.	Estrogen promotes NO signaling and antioxidant defense; its loss post-menopause increases vascular fragility and female LC vulnerability.	LPS, IL-6, TNF-α, ROS, NO, NE, estrogen
2. Immune/Inflammatory	Microbial antigens cross a leaky gut barrier, triggering systemic immune activation. Cytokines activate LC microglia and astrocytes.	Chronic inflammation and oxidative load overwhelm LC’s metabolic demand; neuromelanin shifts from antioxidant to pro-oxidant, causing mitochondrial injury.	Females exhibit stronger immune reactivity; estrogen decline augments glial activation and cytokine release.	IL-6, IL-1β, TNF-α, neuromelanin, estrogen, microglia
3. Hormonal/Endocrine	Gut microbiota regulates estrogen metabolism through β-glucuronidase and hydroxysteroid dehydrogenase activity; dysbiosis lowers estradiol.	Reduced estrogen decreases NE synthesis (via tyrosine hydroxylase) and antioxidant protection, lowering LC resilience.	In females, microbial and ovarian estrogen decline converge after menopause; males rely more on androgen pathways.	β-glucuronidase, estradiol, ERα/ERβ, TH, COMT
4. Vagal/Neuroautonomic	Vagal afferents from gut → NTS → LC; dysbiosis alters gut peptides and cytokines, aberrantly activating vagal input to the HPA axis.	Shifts LC firing from adaptive phasic to stress-like tonic mode, impairing attention and stress regulation.	Females have more vagal fascicles and estrogen receptors in vagal nuclei; fluctuating GABA tone during cycle increases visceral sensitivity.	IL-1β, TNF-α, CCK, GLP-1, ghrelin, PYY, CRF, estrogen
5. Metabolic/Neurochemical	Microbial metabolites (SCFAs, bile acids, tryptophan derivatives) influence energy metabolism and neurotransmitter synthesis.	SCFA loss increases oxidative stress; altered bile-acid and tryptophan pathways disturb catecholaminergic stability in LC.	Males have larger bile-acid pools; estrogen modulates FXR/TGR5 signaling and its decline removes metabolic buffering in females.	Butyrate, bile acids, FXR, TGR5, serotonin, kynurenine, estrogen

BBB: blood–brain barrier; CCK: cholecystokinin; COMT: catechol-O-methyltransferase; CRF: corticotropin-releasing factor; E2: estradiol (estrogen); ERα/ERβ: estrogen receptor alpha/beta; FXR: farnesoid X receptor; GLP-1: glucagon-like peptide-1; IL-1β, IL-6: interleukin-1 beta, interleukin-6; LC: locus coeruleus; LPS: lipopolysaccharide; NE: norepinephrine; NO: nitric oxide; NTS: nucleus tractus solitarius; PYY: peptide YY; ROS: reactive oxygen species; SCFAs: short-chain fatty acids; TH: tyrosine hydroxylase; TNF-α: tumor necrosis factor alpha; TGR5: Takeda G protein-coupled receptor 5

Empirical data support the reversibility of this vulnerability. In the LC-targeted pretangle-tau rat model by Flynn et al. (2025), chronic synbiotic (probiotic + prebiotic) treatment enhanced microbial diversity, enriched Bifidobacterium Lactis, and boosted SCFA-producing microbiome. These changes lowered systemic cytokine levels, and reversed LC microgliosis and BBB leakage. Behaviorally, treated animals displayed improved spatial learning and reduced anxiety, reflecting normalized LC-cortical NE transmission. At the molecular level, notably, females exhibited activation of resilience pathways, such as GSK-3β inhibition in the hippocampus, a major LC target [43].

These findings demonstrate that LC sensitivity to dysbiosis is dynamic and therapeutically modifiable. Restoring gut-brain homeostasis stabilizes LC signaling and protects noradrenergic integrity. Translationally, this supports a precision-medicine strategy that integrates microbiome modulation, vagus-based neuromodulation, and hormonal support to delay LC-linked cognitive decline, particularly in women who are predisposed to AD [179].

Translational implications and future directions

Emerging technologies now allow the integration of LC-specific imaging, systemic biomarkers, and microbiome profiling to define prodromal windows of noradrenergic vulnerability. Longitudinal studies combining neuromelanin-sensitive LC-MRI with plasma/CSF inflammatory signatures and microbial diversity metrics should incorporate sex-based stratification across menopausal state, hormone therapy, and contraceptive exposure. Such multidimensional modeling will help resolve how hormonal transitions interact with microbial composition to shape LC decline and may reveal precision windows for targeted intervention.

In preclinical systems, mechanistic studies should pair LC-centric physiological and molecular readouts including firing dynamics, NE release, BBB integrity, microglial activation, and transcriptomic remodeling, with gut-brain interventions such as probiotics, prebiotics, dietary modulation, and vagus nerve stimulation. Explicit evaluation of sex x treatment interactions will be critical for uncovering differential resilience mechanisms. The LC-targeted pretangle-tau model is especially well-suited for pre-clinical therapeutic testing, enabling multimodal outcome mapping from ultrastructure and immunohistochemistry to kinase signaling pathways linking microbial ecology to LC cellular stress.

Looking forward, personalized intervention strategies should anticipate sex-specific therapeutic responses across both pharmacological and microbial domains. Precision probiotic strain selection or dosing, sex-differentiated neuromodulatory targets (e.g., anti-CRF approaches or adrenergic receptor tuning), and combinatorial regimens integrating microbiome modulation, lifestyle factors, and neuromodulatory therapies may together provide a framework to buffer LC vulnerability across aging trajectories.

Outstanding questions

• Which microbial metabolites (SCFAs, bile acids, tryptophan derivatives) most strongly couple to LC stress biology, and do their brain entry routes differ by sex and age?

• Could integrating neuromelanin-sensitive LC-MRI with plasma metabolomics yield a practical, minimally invasive biomarker panel for early detection of LC decline and for stratifying women by menopausal status and metabolic risk?

• In probiotic/prebiotic responders, are benefits mediated primarily by vascular/immune normalization, vagal recalibration, or intracellular kinase shifts, and do these pathways differ by sex?

Conclusions

Together, the evidence reviewed here suggests that gut dysbiosis is not a passive correlate of AD but an upstream biological driver capable of shaping neural vulnerability. Microbial imbalance, reduced SCFA production, altered metabolite profiles, and heightened inflammatory tone converge with vagal, endocrine, and metabolic signaling to destabilize LC homeostasis, a critical early site of AD pathology. We highlight that these pathways interact strongly with biological sex: females exhibit greater inflammatory reactivity, distinct microbial trajectories across ageing, and experience abrupt estrogen loss, all of which amplify the impact of dysbiosis on LC integrity and cognitive decline.

Importantly, the relationship appears reversible. Microbiome restoration through diet, probiotics, prebiotics, FMT, or metabolic modulation improves cognition and reduces neuroinflammation in animal models and emerging clinical trials, underscoring the gut as a modifiable therapeutic target. We propose that future work must test whether preserving microbial diversity can stabilize LC function, slow tau propagation, and delay disease onset, particularly in women, who bear disproportionate AD risk. A mechanistic focus on the gut-LC-sex axis may open new intervention windows long before traditional clinical decline emerges.

Abbreviations

AD

Alzheimer’s Disease

APP

Amyloid precursor protein

BBB

Blood-brain barrier

CRF

Corticotropin-releasing factor

FMT

Fecal microbiota transplantation

FXR

Farnesoid X receptor

GLP-1

Glucagon-like peptide-1

HPA

Hypothalamic-pituitary axis

LC

Locus coeruleus

LPS

Lipopolysaccharides

MCI

Mild cognitive impaired

NE

Norepinephrine

NO

Nitric-oxide

NTS

Nucleus tractus solitarius

ROS

Reactive oxygen species

SCFA

Short-chain fatty acid

Author contributions

Conceptualization: QY; Writing- original draft: HMS, DSB, EBSMT; QY; Writing- review and editing: HMS, DSB, QY; Visualization: HMS, DSB, QY; Funding Acquisition: QY.

Funding

This work was supported by a Canadian Institutes of Health Research project grant to QY (PJT-197770). HMS is supported by an Ageing Research Council - Newfoundland (ARC-NL) Graduate Fellowship.

Data availability

Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Declaration of Generative AI Use

The authors used GPT-5 (OpenAI) to improve the clarity and style of the text. The authors take full responsibility for the content of the manuscript.